Evaluation of a new protamine titration method to assay heparin in whole blood and plasma

American Journal of Clinical Pathology

Volumn 107, Issue 5, 1997, Pages 511-520

  Schlueter, Annette J ^a   Pennell, Beverly J ^a   Olson, John D ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Factor Xa inhibition assay; Heparin; Point of care testing; Protamine titration

Indexed keywords

ANTITHROMBIN III; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CHROMOGENIC SUBSTRATE; HEPARIN; PROTAMINE; REAGENT;

ADULT; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; FEMALE; HEMATOCRIT; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOSIS; TITRIMETRY;

EID: 0030972451     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/107.5.511     Document Type: Article

References (20)

1. College of American Pathologists. Comprehensive Coagulation Survey, Set CG2-A, Participant Summary. Northfield, Ill: College of American Pathologists; 1995.
2. Hirsh J, van Aken WG, Galus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691-695.
3. Basu D, Gallus A, Hirsch J, et al. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med. 1972;279:324-327.
4. Holm HA. Amidolytic heparin assay (Coatest Heparin) and correlation to clinical effects in heparin treatment of deep venous thrombosis (DVT). Acta Chir Scand. 1982;509(suppl):115-116.
5. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med. 1986;315:1109-1114.
6. Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a "standard care" nomogram. Ann Intern Med. 1993;119:874-881.
7. D'Angelo A, Seveso MP, D'Angelo SV, et al. Effect of clot-detection methods and reagents on activated partial thromboplastin time (APTT). Am J Clin Pathol. 1990;94:297-306.
8. Bain B, Forster T, Sleigh B. Heparin and the activated partial thromboplastin time: a difference between the in-vitro and in-vivo effects and implications for the therapeutic range. Am J Clin Pathol. 1980;74:668-673.
9. Scialla SJ. Heparin monitoring by activated partial thromboplastin time. Am J Clin Pathol. 1985;84:351-354.
10. Zanke B, Shojania AM. Comparison of two APTT methods of monitoring heparin therapy. Am J Clin Pathol. 1990;93:684-689.
11. Kitchen S, Jennings I, Woods TAL, et al. Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. J Clin Pathol. 1996;49:10-14.
12. Brill-Edwards P, Ginsberg JS, Johnston M, et al. Establishing a therapeutic range for heparin therapy. Ann Intern Med. 1993;119:104-109.
13. Van der Velde EA, Poller L. The APTT monitoring of heparin: the ISTH/ICSH collaborative study. Thromb Haemost. 1995;73:73-81.
14. Reed SV, Haddon ME, Denson KWE. An attempt to standardize the APTT for heparin monitoring, using the P.T. ISI/INR system of calibration: results of a 13 centre study. Thromb Res. 1994;74:515-522.
15. Fey MF, Lang M, Furlan M, et al. Monitoring of heparin therapy with the activated partial thromboplastin time and chromogenic substrate assays. Thromb Haemost. 1987;58:853-855.
16. Groce JB III, Gal P, Douglas JB, et al. Heparin dosage adjustment in patients with deep-vein thrombosis using heparin concentrations rather than activated partial thromboplastin time. Clin Pharm. 1987;6:216-222.
17. van den Besselaar AMHP, Meeuwisse-Braun J, Jansen-Gruter R, et al. Monitoring heparin therapy by the activated partial thromboplastin time: the effect of pre-analytical conditions. Thromb Haemost. 1987;57:226-231.
18. Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med. 1994;154:49-56.
19. Ewald GA. Disorders of hemostasis: antithrombotic therapy. In: Ewald GA, McKenzie CR, eds. Manual of Medical Therapeutics. 28th ed. Boston, Mass: Little, Brown; 1995:398-101.
20. Handin RI. Anticoagulant and fibrinolytic therapy. In: Isselbacher KJ, Braunwald E, Wilson JD, et al, eds. Harrison's Principles of Internal Medicine. 13th ed. New York, NY: McGraw-Hill; 1994:1810-1813.